The AβCC Peptide™ Technology

The AβCC peptide™ technology is a great tool for improving the productivity in the field of Alzheimer’s disease therapeutics. The technology effectively solves the problem associated with developing therapeutics against the metastable soluble amyloid-β (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process.


Specific Targeting of Aβ Toxins (“Oligomers”)

Alzinova’s mission is to bring true disease-modifying therapy and diagnostics to Alzheimer’s disease patients. By using the proprietary AβCC technology, Alzinova can develop a theragnostic that is unique in that it targets/detects Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.